Claims:

1. Compound of the formula



(I)

where

R_1 is a) hydrogen, hydroxyl or amino; or

is b) C_1-C_8-alkyl, C_3-C_8-cycloalkyl, C_1-C_8-alkanoyl, C_1-C_8-alkoxycarbonyl, aryl-C_0-C_4-alkyl or heterocyclyl-C_0-C_4-alkyl, which radicals may be substituted by 1-4 C_1-C_8-alkyl, halogen, cyano, oxide, oxo, trifluoromethyl, C_1-C_8-alkoxy, C_1-C_8-alkoxycarbonyl, aryl or heterocyclyl;

R_2 is a) C_1-C_8-alkyl, C_3-C_8-cycloalkyl, C_1-C_8-alkylsulphonyl, C_3-C_8-cycloalkylsulphonyl, aryl-C_0-C_8-alkylsulphonyl, heterocyclylsulphonyl, C_3-C_{12}-cycloalkyl-C_1-C_8-alkanoyl, C_3-C_{12}-cycloalkyl-C_3-C_8-cycloalkanoyl, aryl-C_1-C_8-alkanoyl, aryl-C_3-C_8-cycloalkanoyl, C_1-C_8-alkanoyl, C_1-C_8-alkoxycarbonyl, optionally N-mono- or N,N-di-C_1-C_8-alkylated carbamoyl-C_0-C_8-alkyl, aryl-C_0-C_4-alkyl or heterocyclyl-C_0-C_4-alkyl, which radicals may be substituted by 1-4 C_1-C_8-alkyl, C_3-C_8-cycloalkyl, C_3-C_8-cycloalkoxy, amino, C_{1-6}-alkylamino, di-C_{1-6}-alkylamino, C_0-C_6-alkylcarbonylamino, halogen, cyano, hydroxyl, oxide, oxo, trifluoromethyl, C_1-C_8-alkoxy, optionally N-mono- or N,N-di-C_1-C_8-alkylated carbamoyl, C_1-C_8-alkoxycarbonyl, C_{1-6}-alkylene-dioxy, aryl or heterocyclyl; or

is b) together with R_1 and the nitrogen atom to which they are bonded, a saturated or partly unsaturated 4-8-membered heterocyclic ring which may contain an additional nitrogen, oxygen or sulphur atom or an -SO- or -SO2- group, in which case the additional nitrogen atom may optionally be substituted by C_1-C_8-alkyl, C_1-C_8-alkanoyl, C_1-C_8-alkoxycarbonyl, aryl or heterocyclyl radicals, and this heterocyclic ring may be part of a bicyclic or tricyclic ring system having a total of up to 16 members, and the second ring may also contain a nitrogen, oxygen or sulphur atom or an -SO- or -SO2- group, and the nitrogen atom of the second ring may optionally be substituted by C_1-C_8-alkyl, C_1-C_8-alkanoyl, C_1-C_8-alkoxycarbonyl, aryl or heterocyclyl radicals and all ring systems mentioned may be substituted by 1-4 C_1-C_8-alkyl, halogen, hydroxyl, oxide, oxo, trifluoromethyl, C_1-C_8-alkoxy, C_1-C_8-alkoxy-C_1-C_8-alkyl, C_1-C_8-alkoxy-C_1-C_8-alkoxy, C_1-C_8-alkoxycarbonylamino, C_1-C_8-alkylcarbonylamino, C_1-C_8-alkyl-

amino, N,N-di-C_1-C_8-alkylamino, aryl-C_0-C_4-alkyl, aryloxy-C_0-C_4-alkyl, aryl-C_0-C_4-alkyl-C_1-C_8-alkoxy, aryloxy-C_0-C_4-alkyl-C_1-C_8-alkoxy, heterocyclyl-C_0-C_4-alkyl, heterocyclyloxy-C_0-C_4-alkyl, heterocyclyl-C_0-C_4-alkyl-C_1-C_8-alkoxy or heterocyclyloxy-C_0-C_4-alkyl-C_1-C_8-alkoxy;
R_3 is hydrogen, C_1-C_8-alkyl, C_1-C_8-alkoxycarbonyl or C_1-C_8-alkanoyl;
R_4 is hydrogen, C_1-C_8-alkyl, C_1-C_8-alkoxycarbonyl or C_1-C_8-alkanoyl;R_5 are each independently hydrogen or C_1-C_8-alkyl, or, together with the carbon atom to which they are bonded, are a C_3-C_8-cycloalkylidene radical;
R is an optionally substituted unsaturated carbocyclic or heterocyclic radical;
one of the X_1 and X_2 radicals is carbonyl and the other is methylene;
or salt or prodrug thereof, or where one or more atoms are replaced by their stable, non-radioactive isotopes.

2. Compound of the formula I according to Claim 1, where

R_1 is a) hydrogen; or

is b) C_1-C_8-alkyl or C_3-C_8-cycloalkyl;

R_2 is a) C_1-C_8-alkyl, C_3-C_8-cycloalkyl, C_1-C_8-alkanoyl, heterocyclyl-C_1-C_8-alkanoyl, C_3-C_{12}-cycloalkyl-C_1-C_8-alkanoyl or aryl-C_1-C_8-alkanoyl, which radicals may be substituted by 1-4 C_1-C_8-alkyl, C_3-C_8-cycloalkyl, C_3-C_8-cycloalkoxy, C_{1-6}-alkylamino, cyano, halogen, hydroxyl, oxide, C_0-C_6-alkylcarbonylamino, C_1-C_8-alkoxy, oxo, trifluoromethyl or aryl; or

is b) together with R_1 and the nitrogen atom to which they are bonded, a saturated or partly unsaturated, 4-8-membered, heterocyclic ring which may contain an additional nitrogen or oxygen atom, in which case the additional nitrogen atom may optionally be substituted by C_1-C_8-alkyl or C_1-C_8-alkanoyl, and this heterocyclic ring may be part of a bicyclic or tricyclic ring system having a total of up to 16 members and the second ring may also contain a nitrogen or oxygen atom, and the nitrogen atom of the second ring may optionally be substituted by C_1-C_8-alkyl or C_1-C_8-alkanoyl, and all ring systems mentioned may be substituted by 1-4 C_1-C_8-alkyl, hydroxyl, oxo, oxide, C_1-C_8-alkoxy, C_1-C_8-alkoxy-C_1-C_8-alkoxy, C_1-C_8-alkylcarbonylamino or aryloxy-C_0-C_4-alkyl-C_1-C_8-alkoxy.

3. Compound of the formula I according to Claim 1, where

R is a 2-R_A-4-R_C-phenyl radical, 2-R_A-pyridin-3-yl radical or 3-R_A-pyridin-2-yl radical,

where

R_A is C_1-C_4-alkoxy-C_1-C_4-alkyl such as propyloxymethyl, morpholino-C_1-C_4-alkyl such as 2-morpholinoethyl or 3-morpholinopropyl, C_1-C_8-alkanoylpiperazino-C_1-C_4-alkyl such as N'-acetylpiperazinomethyl, C_1-C_8-alkoxy such as propyloxy, C_1-C_4-alkoxy-C_1-C_5-alkoxy such as 2-methoxyethoxy, 3-methoxypropyloxy, 4-methoxybutyloxy or 5-methoxypentyloxy, C_1-C_4-alkoxy-C_2-C_4-alkenyloxy such as 4-methoxybut-2-enyloxy, C_1-C_4-alkoxy-C_1-C_4-alkoxy-C_1-C_4-alkoxy such as 2-(methoxymethoxy)ethoxy or 2-(2-methoxyethoxy)ethoxy, amino-C_1-C_4-alkoxy such as 2-aminoethoxy or 3-aminopropyloxy, di-C_1-C_4-alkylamino-C_1-C_4-alkoxy such as 3-dimethylaminopropyloxy, C_1-C_8-alkanoyl-amino-C_1-C_4-alkoxy such as N-acetylaminoethoxy, C_1-C_8-alkanoyl-amino-C_1-C_4-alkyl such as N-acetylaminoethyl, carbamoyl-C_1-C_4-alkoxy such as 2-carbamoylethoxy or carbamoyl, and

R_C is hydrogen, di-C_1-C_4-alkylamino-C_1-C_4-alkyl such as dimethylaminomethyl, piperidino-C_1-C_4-alkyl such as piperidinomethyl, pyrrolidino-C_1-C_4-alkyl such as pyrrolidinomethyl, morpholino-C_1-C_4-alkyl such as morpholinomethyl, C_1-C_8-alkanoylpiperazino-C_1-C_4-alkyl such as N'-acetylpiperazinomethyl, or C_1-C_4-alkylpiperazino-C_1-C_4-alkyl such as N'-methylpiperazinomethyl, morpholino, C_1-C_4-alkoxy such as methoxy, morpholino-C_1-C_4-alkoxy such as 2-morpholinoethoxy or 3-morpholinopropyloxy, morpholino-C_1-C_4-alkylcarbamoyl-C_1-C_4-alkoxy such as 2-morpholinoethylcarbamoylmethoxy, piperidino-C_1-C_4-alkoxy such as 2-piperidinoethoxy, carboxyl, carbamoyl, C_1-C_4-alkylcarbamoyl such as methylcarbamoyl, carboxy-C_1-C_4-alkoxy such as carboxymethoxy, di-C_1-C_4-alkylamino-C_1-C_4-alkoxy, such as 3-dimethylaminopropyloxy, C_1-C_8-alkylcarbamoyl-C_1-C_4-alkoxy such as butylcarbamoylmethoxy, or tetrazolyl-C_1-C_4-alkoxy, such as tetrazol-5-ylmethoxy,

4. Compound according to Claim 1 of the formula Ia



(Ia)

where R, R_1, R_2, R_3, R_4, R_5, X_1 and X_2 are each as defined in Claim 1.

5. Compound according to Claim 1 of the formula Ia



(Ia)

where

R_1 is a) hydrogen; or

is b) C_1-C_8-alkyl or C_3-C_8-cycloalkyl;

R_2 is a) C_1-C_8-alkyl, C_3-C_8-cycloalkyl, C_1-C_8-alkanoyl, heterocyclyl-C_1-C_8-alkanoyl, C_3-C_{12}-cycloalkyl-C_1-C_8-alkanoyl or aryl-C_1-C_8-alkanoyl, which radicals may be substituted by 1-4 C_1-C_8-alkyl, C_3-C_8-cycloalkyl, C_3-C_8-cycloalkoxy, C_{1-6}-alkylamino, cyano, halogen, hydroxyl, oxide, C_0-C_6-alkylcarbonylamino, C_1-C_8-alkoxy, oxo, trifluoromethyl or aryl; or

is b) together with R_1 and the nitrogen atom to which they are bonded, a saturated or partly unsaturated, 4-8-membered, heterocyclic ring which may contain an additional nitrogen or oxygen atom, in which case the additional nitrogen atom may optionally be substituted by C_1-C_8-alkyl or C_1-C_8-alkanoyl, and this heterocyclic ring may be part of a bicyclic or tricyclic ring system having a total of up to 16 members and the second ring may also contain a nitrogen or oxygen atom, and the nitrogen atom of the second ring may optionally be substituted by C_1-C_8-alkyl or C_1-C_8-alkanoyl, and all ring systems mentioned may be substituted by 1-4 C_1-C_8-alkyl, hydroxyl, oxo, oxide, C_1-C_8-alkoxy, C_1-C_8-alkoxy-C_1-C_8-alkoxy, C_1-C_8-alkylcarbonylamino or aryloxy-C_0-C_4-alkyl-C_1-C_8-alkoxy;

R_3 and R_4 are each hydrogen,

R_5 is C_1-C_4-alkyl, such as methyl or isopropyl,

R is a 2-R_A-4-R_C-phenyl radical, 2-R_A-pyridin-3-yl radical or 3-R_A-pyridin-2-yl radical, where

R_A is C_1-C_4-alkoxy-C_1-C_4-alkyl such as propyloxymethyl, morpholino-C_1-C_4-alkyl such as 2-morpholinoethyl or 3-morpholinopropyl, C_1-C_8-alkanoylpiperazino-C_1-C_4-alkyl such as N'-acetylpiperazinomethyl, C_1-C_8-alkoxy such as propyloxy, C_1-C_4-alkoxy-C_1-C_5-alkoxy such as 2-methoxyethoxy, 3-methoxypropyloxy, 4-methoxybutyloxy or 5-methoxypentyloxy, C_1-C_4-alkoxy-C_2-C_4-alkenyloxy such as 4-methoxybut-2-enyloxy, C_1-C_4-alkoxy-C_1-C_4-alkoxy-C_1-C_4-alkoxy such as 2-(methoxymethoxy)ethoxy or 2-(2-methoxyethoxy)ethoxy, amino-C_1-C_4-alkoxy such as

2-aminoethoxy or 3-aminopropyloxy, di-C_1-C_4-alkylamino-C_1-C_4-alkoxy such as 3-dimethylaminopropyloxy, C_1-C_8-alkanoyl-amino-C_1-C_4-alkoxy such as N-acetylaminoethoxy, C_1-C_8-alkanoyl-amino-C_1-C_4-alkyl such as N-acetylaminoethyl, carbamoyl-C_1-C_4-alkoxy such as 2-carbamoylethoxy or carbamoyl, and

R_C is hydrogen, di-C_1-C_4-alkylamino-C_1-C_4-alkyl such as dimethylaminomethyl, piperidino-C_1-C_4-alkyl such as piperidinomethyl, pyrrolidino-C_1-C_4-alkyl such as pyrrolidinomethyl, morpholino-C_1-C_4-alkyl such as morpholinomethyl, C_1-C_8-alkanoylpiperazino-C_1-C_4-alkyl such as N'-acetylpiperazinomethyl, or C_1-C_4-alkylpiperazino-C_1-C_4-alkyl such as N'-methylpiperazinomethyl, morpholino, C_1-C_4-alkoxy such as methoxy, morpholino-C_1-C_4-alkoxy such as 2-morpholinoethoxy or 3-morpholinopropyloxy, morpholino-C_1-C_4-alkylcarbamoyl-C_1-C_4-alkoxy such as 2-morpholinoethylcarbamoylmethoxy, piperidino-C_1-C_4-alkoxy such as 2-piperidino-ethoxy, carboxyl, carbamoyl, C_1-C_4-alkylcarbamoyl such as methylcarbamoyl, carboxy-C_1-C_4-alkoxy such as carboxymethoxy, di-C_1-C_4-alkylamino-C_1-C_4-alkoxy, such as 3-dimethylaminopropyloxy, C_1-C_8-alkylcarbamoyl-C_1-C_4-alkoxy such as butylcarbamoylmethoxy, or tetrazolyl-C_1-C_4-alkoxy, such as tetrazol-5-ylmethoxy,

X_1 is methylene and X_2 is carbonyl,
or a salt thereof, in particular a pharmaceutically usable salt thereof.

6. Compound according to one of Claims 1-5 for use in a method for the therapeutic treatment of the human or animal body.

7. Pharmaceutical preparation comprising, as an active pharmaceutical ingredient, a compound according to one of Claim 1-5 in free form or as a pharmaceutically usable salt.

8. Use of a compound according to one of Claims 1-5 for preparing a pharmaceutical preparation having renin-inhibiting action.

9. Use of a compound according to one of Claims 1-5 for preparing a pharmaceutical preparation for the treatment or prevention of hypertension, heart failure, glaucoma, cardiac infarction, kidney failure or restenosis.